http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 15 Jun 2026 08:02:13 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Grifols+launches+FESILTY+fibrinogen+concentrate+in+the+US/26644496.html <p>Grifols (MCE: GRF, NASDAQ: GRFS) announced the US launch of FESILTY, a fibrinogen concentrate approved by the Food and Drug Administration for treating acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency.</p><p>The FDA approved FESILTY in December for patients with congenital fibrinogen deficiency, including hypo- or afibrinogenemia, but not for dysfibrinogenemia. The treatment addresses a rare inherited condition caused by genetic mutations that impair fibrinogen production or function.</p><p>FESILTY provides a purified fibrinogen concentrate that enables rapid restoration of fibrinogen levels during bleeding events. The product can be stored at room temperature and reconstituted in approximately three minutes, http://www.streetinsider.com/Corporate+News/Grifols+launches+FESILTY+fibrinogen+concentrate+in+the+US/26644496.html Mon, 15 Jun 2026 08:02:13 -0400 GIKLY GRF GRF-P GRFS http://www.streetinsider.com/Corporate+News/Grifols+launches+FESILTY+fibrinogen+concentrate+in+the+US/26644496.html <p>Grifols (MCE: GRF, NASDAQ: GRFS) announced the US launch of FESILTY, a fibrinogen concentrate approved by the Food and Drug Administration for treating acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency.</p><p>The FDA approved FESILTY in December for patients with congenital fibrinogen deficiency, including hypo- or afibrinogenemia, but not for dysfibrinogenemia. The treatment addresses a rare inherited condition caused by genetic mutations that impair fibrinogen production or function.</p><p>FESILTY provides a purified fibrinogen concentrate that enables rapid restoration of fibrinogen levels during bleeding events. The product can be stored at room temperature and reconstituted in approximately three minutes, http://www.streetinsider.com/Corporate+News/Grifols+launches+FESILTY+fibrinogen+concentrate+in+the+US/26644496.html Mon, 15 Jun 2026 08:02:13 -0400 GIKLY GRF GRF-P GRFS http://www.streetinsider.com/Corporate+News/Grifols+launches+FESILTY+fibrinogen+concentrate+in+the+US/26644496.html <p>Grifols (MCE: GRF, NASDAQ: GRFS) announced the US launch of FESILTY, a fibrinogen concentrate approved by the Food and Drug Administration for treating acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency.</p><p>The FDA approved FESILTY in December for patients with congenital fibrinogen deficiency, including hypo- or afibrinogenemia, but not for dysfibrinogenemia. The treatment addresses a rare inherited condition caused by genetic mutations that impair fibrinogen production or function.</p><p>FESILTY provides a purified fibrinogen concentrate that enables rapid restoration of fibrinogen levels during bleeding events. The product can be stored at room temperature and reconstituted in approximately three minutes, http://www.streetinsider.com/Corporate+News/Grifols+launches+FESILTY+fibrinogen+concentrate+in+the+US/26644496.html Mon, 15 Jun 2026 08:02:13 -0400 GIKLY GRF GRF-P GRFS http://www.streetinsider.com/Corporate+News/Grifols+launches+FESILTY+fibrinogen+concentrate+in+the+US/26644496.html <p>Grifols (MCE: GRF, NASDAQ: GRFS) announced the US launch of FESILTY, a fibrinogen concentrate approved by the Food and Drug Administration for treating acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency.</p><p>The FDA approved FESILTY in December for patients with congenital fibrinogen deficiency, including hypo- or afibrinogenemia, but not for dysfibrinogenemia. The treatment addresses a rare inherited condition caused by genetic mutations that impair fibrinogen production or function.</p><p>FESILTY provides a purified fibrinogen concentrate that enables rapid restoration of fibrinogen levels during bleeding events. The product can be stored at room temperature and reconstituted in approximately three minutes, http://www.streetinsider.com/Corporate+News/Grifols+launches+FESILTY+fibrinogen+concentrate+in+the+US/26644496.html Mon, 15 Jun 2026 08:02:13 -0400 GIKLY GRF GRF-P GRFS http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Press+Releases/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html <ul type="disc"><li><strong><em>The new fibrinogen concentrate, approved in the U.S. for acute bleeding episodes in pediatric and adult patients with congenital fibrinogen deficiency, is now available in the U.S.</em></strong><br></br><br></br></li><li style="text-align:justify;"><strong><em>FESILTY complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients.</em></strong><br></br></li></ul> <p align="justify">BARCELONA, Spain, June 15, 2026 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced the U.S. launch of its new fibrinogen concentrate. Approved by the U.S. Food and Drug Administration in December for the treatment of acute bleeding episodes in pediatric and adult patients with congenital fibrinogen http://www.streetinsider.com/Globe+Newswire/Grifols+Launches+FESILTY%E2%84%A2+%28fibrinogen%2C+human-chmt%29+in+the+U.S./26644416.html Mon, 15 Jun 2026 08:00:00 -0400 A.06822034 A.23054061 GIKLY GRF GRF-P GRFS O.00303353 O.02094512 O.20026344 http://www.streetinsider.com/Press+Releases/Mason+Capital+Management+to+Support+Grifols+Recommended+Director+Slate+at+Upcoming+Ordinary+General+Meeting/24877416.html <p class="bwalignc"> <b><i>Believes Board Leadership Continuity and Continued Management Focus and Execution Will Drive Long-Term Shareholder Value</i></b> </p> <p> NEW YORK--(BUSINESS WIRE)-- Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today announced that it sent a letter to the Grifols Board of Directors (the “Board”) expressing Mason’s support for the Company’s recommended slate of director candidates for election at the Ordinary General Shareholders’ Meeting to be held on June 4 and 5, 2025. </p><p> The full text of the letter follows: </p><p> May http://www.streetinsider.com/Press+Releases/Mason+Capital+Management+to+Support+Grifols+Recommended+Director+Slate+at+Upcoming+Ordinary+General+Meeting/24877416.html Fri, 30 May 2025 16:05:00 -0400 0RDU GIKLY GRFS O.00303353 http://www.streetinsider.com/Press+Releases/Mason+Capital+Management+to+Support+Grifols+Recommended+Director+Slate+at+Upcoming+Ordinary+General+Meeting/24877416.html <p class="bwalignc"> <b><i>Believes Board Leadership Continuity and Continued Management Focus and Execution Will Drive Long-Term Shareholder Value</i></b> </p> <p> NEW YORK--(BUSINESS WIRE)-- Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today announced that it sent a letter to the Grifols Board of Directors (the “Board”) expressing Mason’s support for the Company’s recommended slate of director candidates for election at the Ordinary General Shareholders’ Meeting to be held on June 4 and 5, 2025. </p><p> The full text of the letter follows: </p><p> May http://www.streetinsider.com/Press+Releases/Mason+Capital+Management+to+Support+Grifols+Recommended+Director+Slate+at+Upcoming+Ordinary+General+Meeting/24877416.html Fri, 30 May 2025 16:05:00 -0400 0RDU GIKLY GRFS O.00303353 http://www.streetinsider.com/Press+Releases/Mason+Capital+Management+to+Support+Grifols+Recommended+Director+Slate+at+Upcoming+Ordinary+General+Meeting/24877416.html <p class="bwalignc"> <b><i>Believes Board Leadership Continuity and Continued Management Focus and Execution Will Drive Long-Term Shareholder Value</i></b> </p> <p> NEW YORK--(BUSINESS WIRE)-- Mason Capital Management LLC (“Mason”), a registered investment advisor to funds and accounts holding approximately 3% of Grifols S.A. (“Grifols” or the “Company”) (BME: GRF) (NASDAQ: GRFS) class A shares, today announced that it sent a letter to the Grifols Board of Directors (the “Board”) expressing Mason’s support for the Company’s recommended slate of director candidates for election at the Ordinary General Shareholders’ Meeting to be held on June 4 and 5, 2025. </p><p> The full text of the letter follows: </p><p> May http://www.streetinsider.com/Press+Releases/Mason+Capital+Management+to+Support+Grifols+Recommended+Director+Slate+at+Upcoming+Ordinary+General+Meeting/24877416.html Fri, 30 May 2025 16:05:00 -0400 0RDU GIKLY GRFS O.00303353